Literature DB >> 9430469

Technetium-99m-furifosmin as an agent for functional imaging of multidrug resistance in tumors.

J R Ballinger1, T Muzzammil, M J Moore.   

Abstract

UNLABELLED: There has been a preliminary report that furifosmin, like the other lipophilic 99mTc cations sestamibi and tetrofosmin, is a substrate for P-glycoprotein, the membrane transporter that is a mechanism of multidrug resistance (MDR) in tumors. This has been further investigated in the rat mammary carcinoma cell line MatB/WT and its doxorubicin-selected resistant variant MatB/AdrR.
METHODS: In vitro studies were performed by adding furifosmin to stirred single-cell suspensions of MatB/WT and MatB/AdrR in the presence or absence of the Pgp-modulating drug PSC833. Dynamic imaging studies over 30 min were performed in rats bearing MatB/WT or MatB/AdrR tumors growing in the leg.
RESULTS: Accumulation of furifosmin in MatB/AdrR cells in vitro was much lower than that in MatB/WT cells. The addition of 1 microM PSC833 increased the plateau accumulation in MatB/AdrR cells 2.4-fold, but did not affect accumulation in MatB/WT cells. In rats, furifosmin accumulated rapidly in MatB/WT tumors and washed out with a mean t3 of 78 min. Washout from MAtB/AdrR tumors was more rapid, with a t3 of 46 min (p < 0.025). Following dissection of animals at 30 min, mean tumor-to-muscle ratios were 1.57 and 1.05 in MatB/WT and MatB/ AdrR tumors, respectively (p < 0.025).
CONCLUSION: Furifosmin is suitable for functional imaging of multidrug resistance in tumors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9430469

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  7 in total

Review 1.  A brief overview of metal complexes as nuclear imaging agents.

Authors:  Douglas S MacPherson; Kimberly Fung; Brendon E Cook; Lynn C Francesconi; Brian M Zeglis
Journal:  Dalton Trans       Date:  2019-10-07       Impact factor: 4.390

2.  To use MIBI or not to use MIBI? That is the question when assessing tumour cells.

Authors:  Jean-Luc Moretti; Nathalie Hauet; Meltem Caglar; Olivier Rebillard; Zeynep Burak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07       Impact factor: 9.236

3.  Imaging recognition of inhibition of multidrug resistance in human breast cancer xenografts using 99mTc-labeled sestamibi and tetrofosmin.

Authors:  Zhonglin Liu; Gail D Stevenson; Harrison H Barrett; Lars R Furenlid; Donald W Wilson; George A Kastis; Michael Bettan; James M Woolfenden
Journal:  Nucl Med Biol       Date:  2005-08       Impact factor: 2.408

Review 4.  99mTc-MIBI in the evaluation of breast cancer biology.

Authors:  Silvana Del Vecchio; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-23       Impact factor: 9.236

5.  Imaging recognition of multidrug resistance in human breast tumors using 99mTc-labeled monocationic agents and a high-resolution stationary SPECT system.

Authors:  Zhonglin Liu; Gail D Stevenson; Harrison H Barrett; George A Kastis; Michael Bettan; Lars R Furenlid; Donald W Wilson; James M Woolfenden
Journal:  Nucl Med Biol       Date:  2004-01       Impact factor: 2.408

6.  Imaging probes for non-invasive tumoral detection and functional monitoring of cancer multidrug resistance.

Authors:  Filipa Mendes; Lurdes Gano; Jorge Grilo; Susana Cunha; Célia Fernandes; António Paulo
Journal:  Cancer Drug Resist       Date:  2020-02-20

7.  Comparison of (99m)Tc-sestamibi and doxorubicin to monitor inhibition of P-glycoprotein function.

Authors:  T Muzzammil; M J Moore; D Hedley; J R Ballinger
Journal:  Br J Cancer       Date:  2001-02-02       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.